translated from German with DeepL

Explosive questions for BioNTech: Why is Cov-19 vaccination in the 2019 Annual Report?

A smart German citizen addressed BioNTech with an open letter - several times. She studied the annual reports closely and compared them with the official "timeline" of the pandemic.

Report24 has also been able to prove several times that Biontech apparently has well-informed soothsayers, because some details happened earlier than the rest of the world could know about them.

Biontech remains silent on all these critical issues - the future will show whether this will also be possible in court.

In context, we also recommend the articles Merkel, Gates, Sahin: Dubious meeting of pandemic drivers already in 2018, Biontech founder Türeci admits: Pandemic preparations already in late 2019.

The open letter - with explosive questions

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Deutschland

service@biontech.de

Augsburg, 09.01.2021

Dear Sir or Madam,

Today I am addressing you with a few questions. You can find your company'sannual report for 2019online at the following link: https://investors.biontech.de/static-files/5e4133c2-6e8f-4ca4-8a65-ffa97007d9eb

Here you can see on page 6 which projects, drugs, immunotherapeutics and vaccines the company is currently working on and how advanced the process is.

Here, as an immunotherapeutic based on mRNA technology, a drug against COVID 19 is listed. One can see that the preclinical study phase has already been completed and phase 1 testing is underway.

Further, one can read that the drug/therapeutic/vaccine is designated BNT 162. The supplementary note reads (asterisk) that this has been the case since 2020.

At the following link you can find a little more about this drug/therapeutic called BNT 162: https://zoonosen.net/covid-19-impfstoffentwicklung

As of July 15, 2020, you can also find the trial phase in which the respective drug is currently being tested. For the substance mentioned, phases 1 to 2 in Germany are indicated here.

Now for my questions:

If you go looking for when the novel pathogen first appeared for the very first time, you will come across this page: https://www.dguv.de/de/praevention/corona/allgemeine-infos/index.jsp

It can be read here that the virus first appeared in China in December 2019. That makes me wonder a bit.

Question 1

How was your company able to develop a therapeutic that had already completed preclinical testing by the end of 2019, when the virus didn't even emerge until December 2019?

I looked again to see if I might have made a mistake in thinking that they were developing therapeutics against corona viruses in general, but that's not the case, because their annual report says that it's a therapeutic against COVID-19.

1/2

>>18293665

Question 2

Your annual report states that it is an immunotherapy based on mRNA technology. Can you please explain to me what the difference is between an immunotherapy and a vaccination? I am a bit confused here, as I was previously of the opinion that the two things are not synonymous.

Further, immunotherapies are more known to pose severe challenges to the immune system, as is the case with immunotherapy using chemo, for example, as you can read here:

https://m.focus.de/gesundheit/ratgeber/krebs/therapie/immuntherapie-schwere-nebenwirkungen-der-immuntherapie_id_4573252.html

Question 3

How long did the individual study and test phases last?

If we follow the descriptions that indicate the average minimum duration of the phases, we read here of a year's duration of a phase in each case.

https://www.vfa.de/de/arzneimittel-forschung/so-funktioniert-pharmaforschung/klinische-studien-uebersicht.html

However, that would mean that the immunotherapeutic for the treatment of COVID 19 would have to have been ready by the end of 2018 at the latest, since - according to the information in your annual report - by the end of 2019, the preclinical test phase had already been fully completed and even half of test phase 1 had already been completed. That would even bring us into 2017.

Here I must be wrong somehow, because how could you already develop something in 2017/2018 against a disease that appeared for the first time in December 2019? Where is my thinking error here?

The test phases

Further question in relation to the test phases: How long did the individual test phases last and when was test phase 3 completed? I do not get along with the stated durations of the individual test phases. Because as can be read in the link above, each phase lasts - I repeat myself and apologize for this - about 1 year.

The vaccine (is it even one, or is it an immunotherapy? - see question above) has been in global use since December 2020. If we now assume, according to their annual report, that by the end of 2019 the preclinical phase was complete (1 year) and half of the phase 1 testing was completed (1/2 year), this would mean that phase 1 testing was completed around mid-2020 and then (mid-2020) phase 2 testing could begin. This would then last until about mid-2021, at which point Phase 3 testing could begin (testing the substance on many sick people).

I seem to recall that the duration of the various test phases were shortened due to urgency. Is this true? And to what duration were they shortened? From a purely mathematical point of view, this must be a massive reduction in the usual duration.

In fact, I am just a normal citizen who is simply interested and wants to understand.

So it would be very nice of you if you could answer my questions and show me why so much contradictory information is circulating and explain my errors in thinking. I must be definitely mistaken here, can only alone not discover my errors and am therefore very grateful to you if I could get the explanatory and plausible facts supplied by you.

Thank you for your time

I look forward to your responses.

With kind regards

Nadine Rebel

The company Biontech has not yet responded to this letter.

https://report24.news/brisante-fragen-an-biontech-weshalb-ist-cov-19-impfung-im-2019-geschaeftsbericht/

1. Feb 2022

2/2